Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 467-473, May 2008

Cerebral kinetics of the dopamine D2 receptor ligand [123I]IBZM in mice

  • Philipp T. Meyer

      Affiliations

    • Department of Neurology, University Hospital Aachen, 52074 Aachen, Germany
    • Department of Nuclear Medicine, University Hospital Aachen, 52074 Aachen, Germany
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, University Hospital Aachen, 52074 Aachen, Germany. Tel.: +49 241 8088743; fax: +49 241 8082520.
  • ,
  • Dagmar Salber

      Affiliations

    • C. & O. Vogt Institute of Brain Research, University Hospital Duesseldorf, 40225 Duesseldorf, Germany
  • ,
  • Johannes Schiefer

      Affiliations

    • Department of Neurology, University Hospital Aachen, 52074 Aachen, Germany
  • ,
  • Markus Cremer

      Affiliations

    • Institute of Neurosciences and Biophysics, Research Center Juelich, 52425 Juelich, Germany
  • ,
  • Wolfgang M. Schaefer

      Affiliations

    • Department of Nuclear Medicine, University Hospital Aachen, 52074 Aachen, Germany
  • ,
  • Christoph M. Kosinski

      Affiliations

    • Department of Neurology, University Hospital Aachen, 52074 Aachen, Germany
  • ,
  • Karl-Josef Langen

      Affiliations

    • Institute of Neurosciences and Biophysics, Research Center Juelich, 52425 Juelich, Germany

Received 29 November 2007; received in revised form 4 January 2008; accepted 30 January 2008. published online 04 April 2008.

Abstract 

Introduction

In vivo small animal imaging of the dopaminergic system is of great interest for basic and applied neurosciences, especially in transgenic mice. Small animal SPECT is particularly attractive because of its superior spatial resolution and tracer availability. We investigated the kinetics of the commercial dopamine D2 receptor (DZR) ligand [123I]IBZM in mice as a prerequisite for an appropriate design of translational SPECT imaging between mice and humans.

Methods

Cerebral kinetics of [123I]IBZM under isoflurane anaesthesia were assessed by autoradiography in mice sacrificed at 30, 60, 120 and 200 min after iv injection. To explore the possible effects of isoflurane anaesthesia, an additional mice group was only anaesthetized for 20 min before being sacrificed at 140 min (putative time of single-scan SPECT analysis).

Results

Maximum [123I]IBZM uptake in the striatum (D2R-rich; 10.5±2.7 %ID/g) and cerebellum (D2R-devoid; 2.4±0.7 %ID/g) was observed at 30 min after injection. Thereafter, [123I]IBZM uptake decreased slowly in striatum and rapidly in the cerebellum (200 min: 5.3±1.9 and 0.4±0.2 %ID/g, respectively). The striatum-to-cerebellum (S/C) [123I]IBZM uptake ratio increased from 4.6±1.2 at 30 min to 11.6±2.6 at 120 min. The S/C ratio at 200 min was highly variable (17.8±10.1), possibly indicating pseudo-equilibration in some animals. In mice, which were only anaesthetized between 120 and 140 min, a higher S/C ratio of 17.0±5.1 was observed.

Conclusions

The present study suggests that [123I]IBZM is a suitable ligand for D2R-SPECT in mice. Although a single-scan analysis may be a pragmatic semi-quantitative approach, tracer kinetic analyses on dynamic SPECT data should be pursued. The interfering effects of isoflurane anaesthesia need to be considered.

Keywords: Small animal imaging, SPECT, Dopamine D2 receptor, [123I]IBZM, Tracer kinetic analysis, Isoflurane anaesthesia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(08)00035-8

doi:10.1016/j.nucmedbio.2008.01.002

Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 467-473, May 2008